Skip to main content
. Author manuscript; available in PMC: 2016 Jul 7.
Published in final edited form as: JCI Insight. 2016 Jun 16;1(9):e86380. doi: 10.1172/jci.insight.86380

Figure 7. Absence of Fbln1c protects against airway remodeling in experimental chronic asthma and pulmonary fibrosis.

Figure 7

WT and Fbln1c−/− mice were administered house dust mite (HDM) extract for 5 days per week for 5 weeks; controls were administered sterile saline. (A) Collagen deposition around small airways in lung sections stained with Verhoeff’s-Van Gieson stain (VVG, left; scale bar: 500 μm). Inserts show expanded image of indicated regions (scale bar: 50 μm). Quantification of collagen deposition normalized to the perimeter of basement membrane (Pbm) (right). n = 24–40 airways from n = 6–8 mice per group. WT and Fbln1c−/− mice were administered bleomycin sulphate once, controls were administered sterile PBS, and tissues were collected 28 days later. (B) Collagen deposition around small airways and normalized to Pbm (scale bar: 500 μm). Inserts show expanded image of indicated regions (scale bar: 50 μm). n = 24–32 airways from n = 8 mice per group. Results are mean ± SEM. **P < 0.01 compared with WT or Fbln1c−/− controls; #P < 0.05, ##P < 0.01 compared with HDM or bleomycin-treated WT controls. Statistical differences were determined with 1-way ANOVA followed by Bonferroni post-test.